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Background: PPM1D (protein phosphatase, Mg2+/Mn2+ dependent, 1D) has been reported to be involved in
multiple human tumors. This study was designed to investigate the functional role of PPM1D in lung cancer cells.
Methods: Expression levels of PPM1D were analyzed in A549 and H1299 cells by real-time PCR and Western
blotting. Lentivirus-mediated short hairpin RNA (shRNA) was used to knock down PPM1D expression in both cell
lines. The effects of PPM1D on lung cancer cell growth were investigated by MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide), colony formation and flow cytometry assays.
Results: Knockdown of PPM1D in lung cancer cells resulted in decreased cell proliferation and impaired colony
formation ability. Moreover, flow cytometry analysis showed that knockdown of PPM1D arrested cell cycle at the
G0/G1 phase. Furthermore, PPM1D silencing downregulated the expression of cyclin B1 in H1299 cells. Therefore,
it is reasonable to speculate that the mechanisms by which PPM1D knockdown alleviates cell growth may be
partly via the induction of cell cycle arrest due to the suppression of cyclin B1.
Conclusions: These results suggest that PPM1D silencing by RNA interference (RNAi) may be a potential
therapeutic approach for the treatment of lung cancer.
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Lung cancer is one of the major causes of death in the
world [1]. The survival rate of lung cancer remains low
despite the development of various treatment modalities
[2,3]. Even with advances in chemotherapy and radio-
therapy, survival rates for patients with advanced stage
disease remain largely unchanged [4]. The best chemo-
therapeutic agents have limited impact with median pa-
tient survival being only 11 to 13 months [5]. This raises
the need for improved treatment methods based on mo-
lecular targeting of lung cancers [6]. The attention paid
to understanding the molecular basis of carcinogenesis
as a path for cancer defense is rapidly increasing [7,8]. It* Correspondence: sknkim@pknu.ac.kr; hupenghp@yeah.net
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phenomena of cancer development would be a more
specific treatment approach. There are a large number
of reports on the successful use of RNA interference
(RNAi) to suppress cancer progression for both in vitro
and in vivo models [9].
PPM1D (protein phosphatase, Mg2+/Mn2+ dependent 1D),
also known as WIP1 (wild-type p53 induced protein
phosphatase 1), is a member of the PP2C family of Ser/
Thr protein phosphatases [10]. PPM1D transcription is
upregulated in response to various types of DNA dam-
age in a p53-dependent manner [11]. Once upregulated,
PPM1D has been shown to dephosphorylate and down-
regulate several targets, particularly proteins associated
with the ATM/ATR-initiated DNA damage response,
including tumor suppressors with a proven role in cancer
susceptibility such as p53 [12], ATM [13] and checkpoint
kinase 2 (Chk2) [14]. There is also accumulating evidence
that PPM1D is involved in oncogenesis. PPM1D ampli-
fication and overexpression have been demonstrated inLtd. This is an Open Access article distributed under the terms of the Creative
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pancreatic adenocarcinoma [16], medulloblastoma [17],
breast cancer [18,19] and ovarian clear cell carcinoma [20].
For breast cancer, ovarian cancer, lung adenocarcinoma
and hepatocellular carcinoma, PPM1D overexpression is
associated with poor survival [21]. However, the functional
role of PPM1D in lung cancer remains unclear.
Therefore, in this study, we examined the role of PPM1D
in cell growth via an RNAi lentivirus system in two human
lung cancer cell lines, A549 and H1299. The effects of
PPM1D on lung cancer cell growth were investigated by
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide), colony formation and flow cytometry assays.
Methods
Reagents and plasmids
Dulbecco’s modified Eagle’s medium (DMEM), RPMI1640
medium and fetal bovine serum (FBS) were obtained from
Hyclone (Logan, UT, USA). Short hairpin RNA (shRNA)
expression vector pFH-L, lentiviral packaging aid vectors
pVSVG-I and pCMVΔR8.92 were purchased from Shanghai
Hollybio (Shanghai, China). RNeasy MidiKit was purchased
from Qiagen (Valencia, CA, USA). AgeI, EcoRI, and SYBR
Green Master Mix Kits were purchased from TaKaRa
(Dalian, China). Lipofectamine 2000 and TRIzol were
purchased from Invitrogen (Carlsbad, CA, USA). M-MLV
reverse transcriptase was purchased from Promega
(Madison, WI, USA). All other chemicals were obtained
from Sigma (St Louis, MO, USA). The antibodies used
were as follows: anti-PPM1D (1:500 dilution; Abcam,
Cambridge, UK), anti-GAPDH (1:5,000 dilution; Santa
Cruz, CA, USA), anti-mouse HRP and anti-rabbit HRP
(1:5,000 dilution; Santa Cruz).
Cell culture
Human lung cancer cell lines, A549 and H1299, and hu-
man embryonic kidney cell line 293 T were obtained from
the cell bank of the Shanghai Institute of Cell Biology.
A549 and 293 T cells were maintained in DMEM supple-
mented with 10% heat-inactivated FBS and penicillin/
streptomycin. H1299 cells were maintained in RPMI1640
medium supplemented with 10% heat-inactivated FBS and
penicillin/streptomycin. All cells were incubated at 37°C in
a humidified atmosphere containing 5% CO2.
Construction of PPM1D short hairpin RNA containing
lentivirus and transduction into lung cancer cells
To construct lentiviruses containing PPM1D shRNA and
control non-silencing shRNA (shCon), the siRNA se-
quences 5′-CCCTTCTCGTGTTTGCTTAAA-3′ and
5′-TTCTCCGAACGTGTCACGT-3′ were used, respect-
ively. These nucleotide sequences were inserted into the
plasmids using a vector expressing pFH-L shRNA. Lentivi-
ruses were generated by triple transfection of 80% confluent293 T cells with modified pFH-L plasmid and pVSVG-I
and pCMV△R8.92 helper plasmids using Lipofectamine
2000. Then the lentiviral particles were harvested by
ultra-centrifugation (4,000 g at 4°C) for 10 min, filtered
through a 45-μm filter, and centrifuged (4,000 g at 4°C)
again for 15 min.
For cell infection, A549 and H1299 cells were cultured
in six-well plates at a density of 5 × 105 cells per well and
transduced with the constructed lentiviruses containing
PPM1D shRNA (Lv-shPPM1D) and non-silencing shRNA
(Lv-shCon) at an MOI of 35 and 20, respectively. The
infection efficiency was measured after 72 h through a
fluorescence microscope by observing the expression of
green fluorescent protein.
RNA extraction and real-time PCR analysis
Total RNA was extracted from cells using TRIzol reagent
and synthesized into cDNA by M-MLV reverse transcript-
ase according to the manufacturer’s instructions. Real-time
quantitative PCR was performed on a BioRad Connect
Real-Time PCR platform using SYBR Green Master Mix
Kit. In brief, each PCR reaction mixture containing 10 μl of
2 × SYBR premix ex taq, 0.8 μl of sense and antisense
primers (2.5 μM), 5 μl of cDNA and 4.2 μl of ddH2O, was
run for 40 cycles with initial denaturation at 95°C for
1 min, denaturation at 95°C for 5 s and extension at 60°C
for 20 s. The forward and reverse primers of PPM1D
were 5′-AGAGAATGTCCAAGGTGTAGTC-3′ and
5′-TCGTCTATGCTTCTTCATCAGG-3′. β-actin was
used as an internal control. The forward and reverse primers
of β-actin were 5′-GTGGACATCCGCAAAGAC-3′ and
5′-AAAGGGTGTAACGCAACTA-3′. Relative gene ex-
pression levels were calculated using 2-ΔΔCT analysis.
Western blot analysis
Cells were collected 6 days after lentivirus infection and
lysed in a radio-immune precipitation assay buffer. The
protein content was measured by the Lowry method. Each
protein sample was adjusted to 2 μg/μl in 20 μl volume
mixed with 2× SDS sample buffer, electrophoresed on a
12% SDS-PAGE gel and transferred to a polyvinylidene
difluoride membrane. The protein levels were detected after
antibody treatment using ECL kit (Amersham, Piscataway,
NJ, USA) by exposure to X-ray film.
MTT assay
Lentivirus-transduced cells were seeded into 96-well plates
at a concentration of 2 × 103 cells per well. Following incu-
bation for 1, 2, 3, 4 or 5 days, 20 μl of MTT (5.0 mg/ml)
was added to each well. Following incubation at 37°C
for 4 h, 200 μl of dimethyl sulfoxide was added to each
well after removing the medium and MTT from the
wells. The absorbance was measured using a micro-plate
reader at 595 nm.
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Lentivirus-transduced cells were seeded into six-well plates
at a concentration of 200 cells per well. The medium was
refreshed every 3 days. After 8 days of culturing, the cells
were washed with PBS and fixed with 4% paraformalde-
hyde. The fixed cells were stained with freshly prepared
Giemsa stain for 20 min. Colonies were counted under
light/fluorescence microscopy.
Cell cycle analysis
The cell cycle distribution was analyzed by flow cytome-
try using propidium iodide staining. After lentivirus in-
fection for 4 days, H1299 cells were seeded on six-well
plates at a density of 5 × 105 cells per well. Then the cells
were collected at 80% confluency, fixed by suspending in
0.7 ml of 70% cold ethanol and incubated for 30 min at
4°C. The ethanol was discarded by centrifugation and
the propidium iodide (100 μg/ml) solution containing
10 μg/ml of DNase-free RNase A was added and incubated
for 30 min. Then the cell suspension was filtered through
a 50-μm nylon mesh, and the stained cells were analyzed
by flow cytometer (FACS Cali-bur, BD Biosciences, San
Diego, CA, USA).
Statistical analysis
All data are presented as mean ± standard deviation (SD)
of at least three independent experiments performed in
triplicate. The statistical analysis used Student’s t-test
and P < 0.05 was considered to be statistically significant.
Ethical approval statement
All experimental research that is reported in this manuscript
has been performed with the approval of the Institutional
Ethics Committee of Tongji University.
Results
Effect of infection by lentiviruses containing PPM1D short
hairpin RNA on PPM1D expression in lung cancer cells
To explore the role of PPM1D in lung cancer, we first
detected the expression levels of PPM1D by real-time
PCR and Western blotting in two lung cancer cell lines,
A549 and H1299. As shown in Figure 1A, B, both cell
lines had PPM1D mRNA and protein expression. How-
ever, the expression level of PPM1D in H1299 cells was
higher than that in A549 cells. To examine the function
of PPM1D in lung cancer cells, we used lentivirus-
mediated shRNA to knock down PPM1D expression in
both A549 and H1299 cells. As shown in Figure 1C, D,
the relative expression levels of PPM1D were signifi-
cantly (P < 0.001) reduced in Lv-shPPM1D infected cells,
compared to non-infected cells and Lv-shCon infected
cells. The knockdown efficiency of PPM1D was calcu-
lated as 61.9% for A549 cells and 65.8% for H1299
cells. Moreover, more than 90% of cells expressed thegreen fluorescence protein, indicating that lentivirus
infection was successful (Figure 1E). There results in-
dicate that the lentiviruses containing PPM1D shRNA
could efficiently suppress the expression of endogenous
PPM1D in lung cancer cells.
Effect of PPM1D short hairpin RNA on the viability of
lung cancer cells
To explore the effect of PPM1D silencing on the viability
of lung cancer cells, an MTT assay was performed for
A549 and H1299 cells. Cell viability was observed for
5 days for non-infected cells, Lv-shCon infected cells and
Lv-shPPM1D infected cells. As depicted in Figure 2A, B,
the growth curve of Lv-shPPM1D infected cells started to
drop from the third day, compared to non-infected cells
and Lv-shCon infected cells. On the fifth day, the differ-
ence for cell viability was significantly wider (P < 0.01),
while there was no difference between non-infected
cells and Lv-shCon infected cells. These results indicate
that knockdown of PPM1D could remarkably inhibit the
viability of lung cancer cells.
Effect of PPM1D short hairpin RNA on the colony-forming
ability of lung cancer cells
To explore the long-term effect of PPM1D silencing on the
proliferation of lung cancer cells, an assay of colony forma-
tion was performed for A549 and H1299 cells. As shown in
Figure 2C, the size of each single colony of Lv-shPPM1D
infected cells was much smaller than for non-infected
cells or Lv-shCon infected cells. Moreover, the number
of colonies was significantly decreased (P < 0.01) for
both A549 and H1299 cells after PPM1D silencing
(Figure 2D, E). These results indicate that knockdown
of PPM1D could remarkably inhibit the proliferation
of lung cancer cells.
Effect of PPM1D silencing on the cell cycle distribution of
H1299 cells
The effect of PPM1D silencing on cell cycle distribution
was analyzed using a flow cytometer. As shown in Figures 3
and 4A, PPM1D knockdown seriously affected the cell
cycle distribution of H1299 cells. The cell percentage for
the G0/G1 phase was significantly increased (P < 0.05) for
Lv-shPPM1D infected cells compared to non-infected cells
and Lv-shCon infected cells. Meanwhile, the cell population
of the S phase showed a marked decrease (P < 0.01) of
H1299 cells after PPM1D silencing. These results indicate
that knockdown of PPM1D could arrest the cell cycle at
the G0/G1 phase. Furthermore, the expression level of
mitosis-related protein cyclin B1 was obviously reduced
in H1299 cells after PPM1D silencing (Figure 4B). Taken
together, we suggest that knockdown of PPM1D can
suppress lung cancer cell growth via a blockade of cell
cycle progression and mitosis.
Figure 1 Expression levels of PPM1D in lung cancer cells. (A) Gene expression levels of PPM1D in A549 and H1299 cells analyzed by
real-time PCR. (B) Protein expression levels of PPM1D in A549 and H1299 cells analyzed by Western blotting. (C) PPM1D gene expression levels in
Lv-shPPM1D infected, Lv-shCon infected and non-infected (Con) A549 cells. (D) PPM1D gene expression levels in Lv-shPPM1D infected, Lv-shCon
infected and non-infected H1299 cells. (E) Light microscopic and florescence microscopic pictures of Lv-shPPM1D infected, Lv-shCon infected
and non-infected A549 and H1299 cells. Values are the mean of three independent experiments; bars represent SD. ***P < 0.001 in comparison
with control. Con, control; GFP, green fluorescent protein.
Zhang et al. World Journal of Surgical Oncology 2014, 12:258 Page 4 of 8
http://www.wjso.com/content/12/1/258
Figure 2 Effect of siRNA-mediated PPM1D knockdown on the proliferation of lung cancer cells. A549 (A) and H1299 (B) cells analyzed
using the MTT assay. (C). Light microscopic and fluorescence microscopic pictures of the colonies of A549 cells. Colonies were stained with
Giemsa staining after 8 days of infection. Number of colonies of Lv-shPPM1D infected, Lv-shCon infected and non-infected A549 (D) and H1299
(E) cells. Values are the mean of three independent experiments; bars represent SD. **P < 0.01 and ***P < 0.001 in comparison with the control.
Con, control; OD, optical density.
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Molecular targeted therapies are now included in the
treatment regimen for lung cancer since they have
been shown to extend progression-free survival and
improve overall survival [22-24]. PPM1D was first
identified in a screen for p53 target genes induced by
ionizing radiation [25], and has been proposed as a
homeostatic regulator of the DNA damage response,
facilitating the return of cells to their normal state after
the repair of damaged DNA [12]. PPM1D could inhibit
p53 signaling, and is putatively oncogenic [26]. In additionto p53 inhibition, PPM1D downregulates p38 mitogen-
activated protein kinase [27,28]. To date, there is accu-
mulating evidence that PPM1D is involved in multiple
human tumors, including neuroblastoma, pancreatic
adenocarcinoma, medulloblastoma, breast cancer, ovarian
cancer and hepatocellular carcinoma, and is a promising
therapeutic target [29].
Gene knockdown using RNAi is an excellent tool for
assessing the functional importance of cancer related genes
in vitro. PPM1D silencing using lentivirus-mediated RNAi
has been identified as a potential therapeutic approach for
Figure 3 Fluorescence-activated cell sorting histograms showing cell cycle distributions of Lv-shPPM1D infected, Lv-shCon infected
and non-infected H1299 cells. Con, control. Each line is the repeats form three independent experiments.
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PPM1D has been identified as a novel prognostic marker
for the survival of patients with lung cancer [31]. In the
present study, we found that PPM1D is expressed in two
human lung cancer cell lines, A549 and H1299. Therefore,Figure 4 Effect of PPM1D knockdown on the cell cycle
distribution of H1299 cells. (A) Percentage of cells residing in
each checkpoint of the cell cycle. (B) Cyclin B1 protein expression
levels of Lv-shPPM1D infected, Lv-shCon infected and non-infected
H1299 cells analyzed by Western blotting. Values are the mean of
three independent experiments; bars represent SD. *P < 0.05 and
**P < 0.01 in comparison with the control. Con, control.to investigate the functional role of PPM1D in lung cancer,
we employed lentivirus-mediated shRNA to knock
down PPM1D expression in both cell lines. Knockdown
of PPM1D in lung cancer cells resulted in decreased cell
proliferation and impaired colony formation ability,
which are in line with a previous report showing that
downregulation of PPM1D by RNAi inhibited proliferation
of glioma cells.
PPM1D plays a crucial role in the DNA damage re-
sponse by inhibiting several cell cycle proteins, includ-
ing p53. To elucidate the underlying mechanism of cell
growth inhibition, cell cycle progression was then analyzed
for H1299 cells after PPM1D silencing. Flow cytometry
analysis showed that knockdown of PPM1D arrested
the cell cycle at the G0/G1 phase. Moreover, PPM1D si-
lencing downregulated the expression of cyclin B1 in
H1299 cells. Therefore, it is reasonable to speculate that
the mechanisms by which PPM1D knockdown alleviates
cell growth may be partly via the induction of cell cycle
arrest due to the suppression of cyclin B1. A previous
study of PPM1D null mice showed that PPM1D exhibits
oncogenic activity in vitro and in vivo, and the oncogenic
function of PPM1D is associated with its phosphatase
activity [11]. Further investigations should be conducted to
unravel the regulatory mechanism of oncogenic phosphat-
ase PPM1D in lung cancer cells.
Collectively, our results demonstrate that PPM1D is
a key player in lung cancer cell growth. This study re-
veals a potential therapeutic approach based on tar-
geting PPM1D and further in vivo studies are planned
to confirm whether it is a potent target for lung cancer
treatment.
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This study provides evidence for the first time that PPM1D
modulates lung cancer cell proliferation via cell cycle
control. PPM1D silencing by RNAi may be a potential
therapeutic approach for the treatment of lung cancer.
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